Jakopovic Boris, Horvatić Anita, Baranasic Jurica, Car Iris, Oršolić Nada, Jakopovich Ivan, Sedić Mirela, Kraljević Pavelić Sandra
Dr Myko San - Health from Mushrooms Co., Zagreb, Croatia.
Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.
Front Pharmacol. 2024 Oct 18;15:1475102. doi: 10.3389/fphar.2024.1475102. eCollection 2024.
Colorectal cancer ranks as the third most common cancer in both men and women, with approximately 35% of cases being stage IV metastatic at diagnosis. Even with treatment advancements, the survival rates for these patients remain suboptimal. There is a significant focus on developing multi-targeted therapies due to the common issue of drug resistance in standard and targeted cancer treatments. Medicinal mushrooms, both as single compounds and as complex extracts, have undergone extensive research. Numerous types of mushrooms have been shown to be safe, effective inhibitors of cancer pathways and strong enhancers of the immune system.
In this study, we performed both qualitative and quantitative proteomic analyses using tandem mass tags (TMT) on CT26 wild type (CT26. WT) colon cancer tissues from Balb/c mice, which were treated with a special blend of medicinal mushroom extracts, either alone or in combination with the chemotherapy drug 5-fluorouracil.
The results showed a notable increase in survival rates and indicated that medicinal mushroom preparation Agarikon Plus, both alone and combined with 5-fluorouracil or another medicinal mushroom preparation Agarikon.1, impedes multiple key processes in colorectal cancer progression. The analysis of differentially expressed proteins in treated groups was done by use of bioinformatics tools and a decrease in ribosomal biogenesis (e.g., RPS3) and translation processes (e.g., RPL14) as well as an increase in unfolded protein response (e.g., DNAJC3), lipid metabolism (e.g., ACOT7), and the tricarboxylic acid cycle (e.g., FH) were observed.
The treatment induced various alterations of known biomarkers and protein clusters critical to the progression and prognosis of colorectal cancer, laying a promising foundation for further translational research on this treatment modality.
结直肠癌是男性和女性中第三大常见癌症,约35%的病例在诊断时为IV期转移性癌症。即使有治疗进展,这些患者的生存率仍然不理想。由于标准和靶向癌症治疗中常见的耐药性问题,人们非常关注开发多靶点疗法。药用蘑菇,无论是单一化合物还是复杂提取物,都已经过广泛研究。许多种类的蘑菇已被证明是癌症通路的安全、有效抑制剂,也是免疫系统的强大增强剂。
在本研究中,我们使用串联质谱标签(TMT)对来自Balb/c小鼠的CT26野生型(CT26.WT)结肠癌组织进行了定性和定量蛋白质组学分析,这些组织用特殊混合的药用蘑菇提取物单独或与化疗药物5-氟尿嘧啶联合处理。
结果显示生存率显著提高,表明药用蘑菇制剂Agarikon Plus单独使用或与5-氟尿嘧啶或另一种药用蘑菇制剂Agarikon.1联合使用时,可阻碍结直肠癌进展中的多个关键过程。通过生物信息学工具对治疗组中差异表达的蛋白质进行分析,观察到核糖体生物发生(如RPS3)和翻译过程(如RPL14)减少,以及未折叠蛋白反应(如DNAJC3)、脂质代谢(如ACOT7)和三羧酸循环(如FH)增加。
该治疗诱导了对结直肠癌进展和预后至关重要的已知生物标志物和蛋白质簇的各种改变,为该治疗方式的进一步转化研究奠定了有前景的基础。